

## Lab publication list (last update: May 2021)

1. Xu X, Tassone B, **Ostano P**, Katarkar A, Proust T, Joseph JM, Riganti C, **Chiorino G**, Kutalik Z, Lefort K and Dotto GP HSD17B7 gene in self-renewal and oncogenicity of keratinocytes from Black versus White populations, *EMBO Mol Medicine*, accepted
2. Galluzzo A, Gallo S, Pardini B, Birolo G, Fariselli P, Boretto P, Vitacolonna A, **Peraldo-Neia C**, Spilinga M, Volpe A, Celentani D, Pidello S, Bonzano A, Matullo G, Giustetto C, Bergerone S, Crepaldi T. Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing. *ESC Heart Fail*. 2021 May 2
3. **Peraldo-Neia C**, Massa A, Vita F, Basiricò M, Raggi C, Bernabei P, **Ostano P**, Casorzo L, Panero M, Leone F, Cavalloni G, Aglietta M. A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. *Cancers (Basel)*. 2021 Apr 23;13(9):2051.
4. Nobili S, Mannini A, Parenti A, Raggi C, Lapucci A, **Chiorino G**, Paccosi S, Di Gennaro P, Vezzosi V, Romagnoli P, Susini T, Coronello M. Establishment and characterization of a new spontaneously immortalized ER-/PR-/HER2+ human breast cancer cell line, DHSF-BR16. *Sci Rep*. 2021 Apr 16;11(1):8340
5. Sulsenti R., Frossi B., Bongiovanni L., Cancila V., **Ostano P.**, Fischetti I., Enriquez C., **Guana F., Chiorino G.**, Tripodo C., Pucillo EE., Colombo MP. and Jachetti E. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. *Front. Immunol.*, 02 March 2021
6. Morani F, Doccini S, **Chiorino G**, Fattori F, Galatolo D, **Sciarrillo E**, Gemignani F, Züchner S, Bertini ES, Santorelli FM. Functional Network Profiles in ARSACS Disclosed by Aptamer-Based Proteomic Technology. *Front Neurol*. 2021 Jan 27;11:603774
7. Nanni S, Aiello A, Salis C, Re A, Cencioni C, Bacci L, Pierconti F, Pinto F, Ripoli C, **Ostano P**, Baroni S, Lazzarino G, Tavazzi B, Pugliese D, Bassi P, Grassi C, Panunzi S, **Chiorino G**, Pontecorvi A, Gaetano C, Farsetti A. Metabolic Reprogramming by Malat1 Depletion in Prostate Cancer. *Cancers (Basel)*. 2020 Dec 22;13(1):E15. doi: 10.3390/cancers13010015. PMID: 33375130
8. **Peraldo-Neia C, Ostano P, Mello-Grand M, Guana F, Gregnanin I**, Boschi D, Oliaro-Bosso S, Pippione AC, Careno A, De Cecco L, Cavalieri S, Micali A, Perrone F, Averono G, Bagnasacco P, Dosdegani R, Masini L, Krengli M, Aluffi-Valletti P, Valente G, **Chiorino G**. AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. *Cell Oncol (Dordr)*. 2020 Nov 19. doi: 10.1007/s13402-020-00571-z. PMID: 33211282
9. Katarkar A, Bottoni G, Clocchiatti A, Goruppi S, Bordignon P, Lazzaroni F, **Gregnanin I, Ostano P**, Neel V, Dotto GP. NOTCH1 gene amplification promotes expansion of Cancer Associated Fibroblast populations in human skin. *Nat Commun*. 2020 Oct 12;11(1):5126. doi: 10.1038/s41467-020-18919-2. PMID: 33046701
10. Calandri E, **Guana F**, Pultrone M, Leuzzi S, **Chiorino G**, Soligo E, Frantellizzi V, Gallina S, Liberatore M, De Vincentis G. Evaluation of Left Ventricular Volumes and Ejection Fraction From Gated Myocardial Perfusion SPECT Processed with "Myovation Evolution": Comparison of three Automated Software Packages Using Cardiac Magnetic Resonance as Reference. *Curr Radiopharm*. 2020 Sep 15.
11. Massa A, Varamo C, Vita F, Tavolari S, **Peraldo-Neia C**, Brandi G, Rizzo A, Cavalloni G, Aglietta M. Evolution of the Experimental Models of Cholangiocarcinoma. *Cancers (Basel)*. 2020 Aug 17;12(8):2308.
12. Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, **Scatolini M, Chiorino G**, Vergani E, Rodolfo M, Maurichi A, Posch C, Matin RN, Harwood CA, Bergamaschi D. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. *Cancer Res*. 2020 Jun 15;80(12):2676-2688

13. Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welte J, Gil V, Yuan W, Vlainic T, Bubendorf L, **Chiorino G**, Gnetti L, Torrano V, Carracedo A, Campese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A. CDCEP1 overexpression drives prostate cancer progression and can be targeted in vivo. *J Clin Invest*. 2020
14. Ricci F, Guffanti F, Affatato R, Brunelli L, Roberta P, Fruscio R, Perego P, Bani MR, **Chiorino G**, Rinaldi A, Bertoni F, Fratelli M, Damia G. Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. *Am J Cancer Res*. 2020 Feb 1;10(2):572-580.
15. **Ostano P, Mello-Grand M, Sesia D, Gregnanin I, Peraldo-Neia C, Guana F**, Jachetti E, Farsetti A, **Chiorino G**. Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma. *Int J Mol Sci*. 2020 Feb 6;21(3):1078.
16. Mapelli S N, Albino D, **Mello-Grand M**, Shinde D, Scimeca M, Bonfiglio R, Bonanno E, **Chiorino G**, Garcia-Escudero R, Catapano C V, Carbone G M. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). *Cancers (Basel)*. 2020 Jan 10
17. Bottoni G, Katarkar A, Tassone B, Ghosh S, Clocchiatti A, Goruppi S, Bordignon P, Jafari P, **Tordini F**, Lunardi T, Hoetzenecker W, Neel V, Lingner J, Paolo Dotto G. CSL controls telomere maintenance and genome stability in human dermal fibroblasts. *Nat Commun*. 2019 Aug 29;10(1):3884
18. Bordignon P, Bottoni G, Xu X, Popescu AS, Truan Z, Guenova E, Kofler L, Jafari P, **Ostano P**, Röcken M, Neel V, Dotto GP. Dualism of FGF and TGF- $\beta$  Signaling in Heterogeneous Cancer-Associated Fibroblast Activation with ETV1 as a Critical Determinant. *Cell Rep*. 2019 Aug 27;28(9):2358-2372.e6.
19. Di Mitri D, Mirinda M, Vasilevska J, Calcinotto A, Delaleu N, Revandkar A, Gil V, Boysen G, Losa M, Mosole S, Pasquini E, D'Antuono R, Masetti M, Zagato E, **Chiorino G, Ostano P**, Rinaldi A, Gnetti L, Graupera M, Martins Figueiredo Fonseca AR, Pereira Mestre R, Waugh D, Barry S, De Bono J, Alimonti A. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. *Cell Rep*. 2019 Aug 20;28(8):2156-2168.e5.
20. Varamo C, **Peraldo-Neia C, Ostano P**, Basiricò M, Raggi C, Bernabei P, Venesio T, Berrino E, Aglietta M, Leone F, Cavalloni G. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. *Cancers (Basel)*. 2019 Apr 11;11(4)
21. Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V, **Chiorino G**, Akkaya BG, Linton KJ, De Laurenzi V, Sala G, Falasca M. ABCC3 is a novel target for the treatment of pancreatic cancer. *Adv Biol Regul*. 2019 Aug;73. pii: S2212-4926(19)30036-3. doi: 10.1016/j.jbior.2019.04.004. Epub 2019 Apr 24.
22. Marranci A, D'Aurizio R, Vencken S, Mero S, Guzzolino E, Rizzo M, Pitto L, Pellegrini M, **Chiorino G**, Greene CM, Polisenio L. Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of BRAF-X1 mRNA. *RNA Biol*. 2019 Jul;16(7):865-878. doi: 10.1080/15476286.2019.1600934. Epub 2019 Apr 19
23. **Peraldo-Neia C**, Scatolini M, Grosso E, Lombardi P, Filippi R, Raggi C, Marchiò C, Cavalloni G, Aglietta M, Leone F. Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. *Cancers (Basel)*. 2019 Mar 30;11(4)
24. Raggi C, Fiaccadori K, Pastore M, Correnti M, Piombanti B, Forti E, Navari N, Abbadessa G, Hall T, Destro A, Di Tommaso L, Roncalli M, Meng F, Glaser S, Rovida E, **Peraldo-Neia C**, Olaizola P,

- Banales JM, Gerussi A, Elvevi A, Droz Dit Busset M, Bhoori S, Mazzaferro V, Alpini G, Marra F, Invernizzi P. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. *Am J Pathol*. 2019 Jul 24. pii: S0002-9440(19)30624-8
25. Robinson DJ, Patel A, Purdie KJ, Wang J, Rizvi H, Hufbauer M, **Ostano P**, Akgül B, **Chiorino G**, Harwood C, Bergamaschi D. Epigenetic regulation of iASPP-p63 feedback loop in cutaneous squamous cell carcinoma. *J Invest Dermatol*. 2019 Jan 30
26. Zizza P, Dinami R, Porru M, Cingolani C, Salvati E, Rizzo A, D'Angelo C, Petti E, Amoreo CA, Mottolose M, Sperduti I, Chambery A, Russo R, **Ostano P**, **Chiorino G**, Blandino G, Sacconi A, Cherfils-Vicini J, Leonetti C, Gilson E, Biroccio A. TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. *Nucleic Acids Res*. 2019 Jan 30
27. Bersini S, Gilardi M, Ugolini GS, Sansoni V, Talò G, Perego S, Zanotti S, **Ostano P**, Mora M, Soncini M, Vanoni M, Lombardi G, Moretti M. Engineering an Environment for the Study of Fibrosis: A 3D Human Muscle Model with Endothelium Specificity and Endomysium. *Cell Rep*. 2018 Dec 26;25(13):3858-3868
28. **Mello-Grand M**, **Gregnanin I**, Sacchetto L, **Ostano P**, Zitella A, Bottoni G, Oderda M, Marra G, Munegato S, Pardini B, Naccarati A, Gasparini M, Gontero P, **Chiorino G**. Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. *Carcinogenesis*. 2018 Nov 19.
29. Clocchiatti A, Ghosh S, Procopio MG, Mazzeo L, Bordignon P, **Ostano P**, Goruppi S, Bottoni G, Katarkar A, Levesque M, Kölblinger P, Dummer R, Neel V, Özdemir BC, Dotto GP. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. *J Clin Invest*. 2018 Nov 5.
30. Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, **Chiorino G**, Cozza G, Chiariello M, Galli A, Polisenio L, Cervelli T. Development of a yeast-based system to identify newhBRAFV600E functional interactors. *Oncogene*. 2018 Sep 20.
31. Bono B, **Ostano P**, Peritore M, **Gregnanin I**, Belgiovine C, Liguori M, Allavena P, **Chiorino G**, Chiodi I, Mondello C. Cells with stemness features are generated from in vitro transformed human fibroblasts. *Sci Rep*. 2018 Sep 14;8(1):13838.
32. Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, **Sacchetto L**, **Chiorino G**, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine, *Oncogene*, 2018 Jul 30.
33. Ruffinatti F, Tapella L, **Gregnanin I**, Stevano A, **Chiorino G**, Canonico PL, Distasi C, Genazzani AA, Lim D. Transcriptional remodeling in primary hippocampal astrocytes from an Alzheimer's disease mouse model. *Curr Alzheimer Res*. 2018 Jun 12
34. **Peraldo-Neia C**, **Ostano P**, Cavalloni G, Pignochino Y, Sangiolo D, De Cecco L, Marchesi E, Ribero D, Scarpa A, De Rose AM, Giuliani A, Calise F, Raggi C, Invernizzi P, Aglietta M, **Chiorino G**, Leone F. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. *BMC Genomics*. 2018 Jun 5;19(1):440
35. Al Labban D, Jo SH, **Ostano P**, Saglietti C, Bongiovanni M, Panizzon R, Dotto GP. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. *J Clin Invest*. 2018 Jun 1;128(6):2581-2599
36. Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, **Ostano P**, Frossi B, Sangaletti S, Chiodoni C, **Chiorino G**, Pucillo CE, Tripodo C, Colombo MP. Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. *Cancer Immunol Res*. 2018 Mar 9

37. Benfodda M, Gazal S, Descamps V, Basset-Seguin N, Deschamps L, Thomas L, Lebbe C, Saiag P, Zanetti R, **Sacchetto L, Chiorino G, Scatolini M**, Grandchamp B, Bensussan A, Soufir N. Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma. *Genes Chromosomes Cancer*. 2018 Jan 23.
38. Giordano L, Gallo F, Petracci E, **Chiorino G**, Segnan N; Andromeda working group. The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol. *BMC Cancer*. 2017 Nov 22;17(1):785.
39. Fusella F, Secli L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, **Mello-Grand M, Singh V, Chiorino G**, Silengo L, Altruda F, Turco E, Morotti A, Oliviero S, Castellano I, Cavallo F, Provero P, Tarone G, Brancaccio M. The IKK/NF- $\kappa$ B signaling pathway requires Morgana to drive breast cancer metastasis. *Nat Commun*. 2017 Nov 21;8(1):1636.
40. Ferraresi A, Titone R, Follo C, Castiglioni A, **Chiorino G**, Dhanasekaran DN, Isidoro C., The protein restriction mimetic Resveratrol is an autophagy inducer stronger than amino acid starvation in ovarian cancer cells *Mol Carcinog*. 2017 Dec;56(12):2681-2691.
41. Pisignano G, Napoli S, Magistri M, Mapelli S, Pastori C, Di Marco S, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, **Mello-Grand M, Chiorino G**, Garcia-Escudero R, Varani G, Carbone G, and Catapano C. A promoter proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers" *Nat Commun*. 2017 May 30;8:15622
42. Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, **Chiorino G**, Aglietta M, Grignani G. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. *Mol Cancer*. 2017 Apr 28;16(1):86.
43. Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Gianneccchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, **Chiorino G**, Pellegrini M, Herlyn M, Osman I, Poliseno L. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. *Oncotarget*. 2017 Apr 11;8(15):25395-25417.
44. Martini P, Paracchini L, Caratti G, **Mello-Grand M**, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A, Bignotti E, Odicino FE, Sartori E, Perego P, Katsaros D, Craparotta I, **Chiorino G**, Cagnin S, Mannarino L, Ceppi L, Mangioni C, **Ghimenti C**, D'Incalci M, Marchini S, Romualdi C. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. *Clin Cancer Res*. 2017 May 1;23(9):2356-2366.
45. **Peraldo Neia C**, Cavalloni G, **Chiorino G**, Ostano P, Aglietta M, Leone F. Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. *Oncotarget*. 2016 Dec 27;7(52):86766-86780.
46. Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, **Chiorino G**, Isidoro C. Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. *Mol Carcinog*. 2016 Oct 27
47. Dallavalle C, Albino D, Civenni G, Merulla J, **Ostano P, Mello-Grand M**, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, **Chiorino G**, Catapano CV, Carbone GM. MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. *J Clin Invest*. 2016 Dec 1;126(12):4585-4602.

48. **Peraldo Neia C**, Cavalloni G, **Chiorino G**, **Ostano P**, Aglietta M, Leone F. Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. *Oncotarget*. 2016 Dec 27;7(52):86766-86780.
49. Raggi C, Correnti M, Sica A, Andersen JB, Cardinale V, Alvaro D, **Chiorino G**, Forti E, Glaser S, Alpini G, Destro A, Sozio F, Di Tommaso L, Roncalli M, Banales JM, Coulouarn C, Bujanda L, Torzilli G, Invernizzi P. Cholangiocarcinoma Stem-like Cells Shapes Tumor-initiating Niche by Regulating Associated Macrophages. *J Hepatol*. 2016 Sep 1
50. Cavalloni G, **Peraldo-Neia C**, Varamo C, **Chiorino G**, Sassi F, Aglietta M, Leone F. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. *Oncotarget*. 2016 Jul 13
51. Menietti E, Xu X, **Ostano P**, Joseph JM, Lefort K, Dotto GP. Negative control of CSL gene transcription by stress/DNA damage response and p53. *Cell Cycle*. 2016 Jul 2;15(13):1767-78
52. Lefort K, **Ostano P**, **Mello-Grand M**, Calpini V, Scatolini M, Farsetti A, Dotto GP, **Chiorino G**. Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer. *Oncotarget*. 2016 Jun 30
53. Cavalloni G, **Peraldo-Neia C**, Sassi F, **Chiorino G**, Sarotto I, Aglietta M, Leone F. Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. *BMC Cancer*. 2016 Feb 11;16(1):90.
54. Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D, **Ostano P**, **Chiorino G**, Lattanzio R, Broggin M, Piantelli M, Maffucci T, Falasca M. Class II phosphoinositide 3-kinase C2 $\beta$  regulates a novel signaling pathway involved in breast cancer progression. *Oncotarget*. 2016 Feb 26.
55. Cavalloni G, **Peraldo-Neia C**, Varamo C, Casorzo L, Dell'Aglio C, Bernabei P, **Chiorino G**, Aglietta M, Leone F. Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. *Tumour Biol*. 2015 Oct 20.
56. Pinessi D, **Ostano P**, Borsotti P, Bello E, Guffanti F, Bizzaro F, Frapolli R, Bani MR, **Chiorino G**, Taraboletti G, Resovi A. Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. *Connect Tissue Res*. 2015 Oct;56(5):355-63.
57. Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, **Ostano P**, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Lefort K, Dotto GP. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. *Nat Cell Biol*. 2015 Sep;17(9):1193-204.
58. Gontero P, Marra G, Soria F, Oderda M, Zitella A, Baratta F, **Chiorino G**, **Gregnanin I**, Daniele L, Cattel L, Frea B, Brusa P. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"? *Prostate*. 2015 Apr 20. doi: 10.1002/pros.22999
59. Borsotti P, Ghilardi C, **Ostano P**, Silini A, Dossi R, Pinessi D, Foglieni C, **Scatolini M**, Lacial PM, Ferrari R, Moscatelli D, Sangalli F, D'Atri S, Giavazzi R, Bani MR, **Chiorino G**, Taraboletti G. Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. *Pigment Cell Melanoma Res*. 2015 Jan;28(1):73-81.
60. Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, **Ostano P**, **Chiorino G**, Bani MR, Damia G, Giavazzi R. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. *Cancer Res*. 2014 Dec 1;74(23):6980-90.
61. Kurinna S, Schäfer M, **Ostano P**, Karouzakis E, **Chiorino G**, Bloch W, Bachmann A, Gay S, Garrod D, Lefort K, Dotto GP, Beer HD, Werner S. A novel Nrf2-miR-29-desmocollin-2 axis regulates desmosome function in keratinocytes. *Nat Commun*. 2014 Oct 6;5:5099.

62. Chikh A, Sanzà P, Raimondi C, Akinduro O, Warnes G, **Chiorino** G, Byrne C, Harwood CA, Bergamaschi D. iASPP is a novel autophagy inhibitor in keratinocytes. *J Cell Sci.* 2014 Jul 15;127(Pt 14):3079-93.
63. Calura E, Martini P, Sales G, Beltrame L, **Chiorino** G, D'Incalci M, Marchini S, Romualdi C. Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles. *Nucleic Acids Res.* 2014;42(11):e96.
64. Brooks YS, **Ostano** P, Jo SH, Dai J, Getsios S, Dziunycz P, Hofbauer GF, Cerveny K, **Chiorino** G, Lefort K, Dotto GP. Multifactorial ER $\beta$  and NOTCH1 control of squamous differentiation and cancer. *J Clin Invest.* 2014 May 1;124(5):2260-76.
65. Miglio U, Oldani A, **Mezzapelle** R, Veggiani C, Paganotti A, Garavoglia M, Boldorini R. KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance. *Pathol Res Pract.* 2014 May;210(5):307-11
66. Lefort K, Brooks Y, **Ostano** P, Cario-André M, Calpini V, Guinea-Viniegra J, Albinger-Hegyí A, Hoetzenecker W, Kolfshoten I, Wagner EF, Werner S, Dotto GP A miR-34a-SIRT6 axis in the squamous cell differentiation network *EMBO J* 2013 Aug 14;32(16):2248-63
67. Resovi A, Pinessi D, **Chiorino** G, Taraboletti G Current understanding of the thrombospondin-1 interactome *Matrix Biol* 2014 Jan 27
68. Sharma N, Repetto D, Aramu S, Grasso S, Russo I, Fiorentino A, **Mello-Grand** M, Cabodi S, **Singh** VK, **Chiorino** G, Turco E, Stefano PD, Defilippi P Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties *Am J Cancer Res* 2013 Jun 20;3(3):290-301
69. Longoni N, Malek A, **Mello-Grand** M, **Ostano** P, Orтели E, Albino D, Pinton S, D'Ambrosio G, Sessa F, Thalmann G, Sarti M, Garcia-Escudero R, **Chiorino** G, Catapano CV and Carbone GM, ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kB and drives prostate cancer progression, *Cancer Res* 2013 May 16
70. Quarona V, Zaccarello G, Chillemi A, Brunetti E, **Singh** VK, Ferrero E, Funaro A, Horenstein AL, Malavasi F CD38 and CD157: a long journey from activation markers to multifunctional molecules *Cytometry B Clin Cytom* 2013 Jul-Aug;84(4):207-17
71. Chillemi A, Zaccarello G, Quarona V, Ferracin M, **Ghimenti** C, Massaia M, Horenstein AL, Malavasi F Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule *Mol Med* 2013 May 20;19:99-108
72. Miglio U, **Mezzapelle** R, Paganotti A, Allegrini S, Veggiani C, Antona J, Gentili S, Monga G, Alabiso O, Boldorini R. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. *Pathol Res Pract.* 2013 Apr;209(4):233-6
73. **Mezzapelle** R, Miglio U, Rena O, Paganotti A, Allegrini S, Antona J, Molinari F, Frattini M, Monga G, Alabiso O, Boldorini R. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. *Br J Cancer.* 2013 Apr 30;108(8):1743-9
74. Callari M, Tiberio P, Cecco LD, Cavadini E, Dugo M, **Ghimenti** C, Daidone MG, Canevari S, Appierto V Feasibility of circulating miRNA microarray analysis from archival plasma samples *Anal Biochem* 2013 Mar 11 [Epub ahead of print]
75. Matin RN, Chikh A, Law Pak Chong S, Mesher D, Graf M, Sanza P, Senatore V, **Scatolini** M, Moretti F, Leigh IM, Proby CM, Costanzo A, **Chiorino** G, Cerio R, Harwood CA, Bergamaschi D p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis *J Exp Med* 2013 Feb 25 [Epub ahead of print]
76. **Ghimenti** C, **Mello-Grand** M, **Grosso** E, **Scatolini** M, Regolo L, Zambelli A, **Chiorino** G Regulation of Aromatase Expression in Breast Cancer Treated with Anastrozole Neoadjuvant Therapy *Exp Ther Med* 5: 902-903 (2013)

77. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, Cavalieri D, **Chiorino** G, Cattoretti G, Mangioni C, Milani R, Torri V, Romualdi C, Zambelli A, Romano M, Signorelli M, Giandomenico SD, D'Incalci M Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer *Eur J Cancer* Aug 13 (2012)
78. Maldi E, Travelli C, Caldarelli A, Agazzone N, Cintura S, Galli U, **Scatolini** M, **Ostano** P, Miglino B, **Chiorino** G, Boldorini R, Genazzani A Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions *Pigment Cell Melanoma Res* Oct 10 doi: 101111/pcmr12037 (2012)
79. Callari M, Dugo M, Musella V, Marchesi E, **Chiorino** G, Grand MM, Pierotti MA, Daidone MG, Canevari S, De Cecco L Comparison of Microarray Platforms for Measuring Differential MicroRNA Expression in Paired Normal/Cancer Colon Tissues *PLoS One* 7: e45105 (2012)
80. Morone S, Lo-Buono N, Parrotta R, Giacomino A, Nacci G, Brusco A, Larionov A, **Ostano** P, **Mello-Grand** M, **Chiorino** G, Ortolan E, Funaro A Overexpression of CD157 Contributes to Epithelial Ovarian Cancer Progression by Promoting Mesenchymal Differentiation *PLoS One* 7: e43649 (2012)
81. Onofri C, Pacifico D, **Ostano** P, **Mello Grand** M, **Ghimenti** C, Parisi B, Mandolino G. Strumenti di genomica funzionale per la tipizzazione dell'origine di coltivazione della patata *Minerva Biotecnologica* 24: 11-22 (2012)
82. Longoni N, Kunderfranco P, Pellini S, **Mello-Grand** M, Pinton s, D'Ambrosio G, Sarti M, Sessa F, **Chiorino** G, Catapano CV, Carbone GM Aberrant expression of the neuronal specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression *Oncogene advance online publication*, 25 June 2012; doi:101038/onc2012245 (2012)
83. Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, **Mello-Grand** M, **Chiorino** G, Catapano CV, Carbone GM, Bonapace IM The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression *Oncogene* 31:4878-4887 (2012)
84. Cutrupi S, Reineri S, Panetto A, **Grosso** E, Caizzi L, Ricci L, Friard O, Agati S, **Scatolini** M, **Chiorino** G, Lykkesfeldt AE, De Bortoli M Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells *Oncogene* 31:4353-4361 (2012)
85. Hu B, Castillo E, Harewood L, **Ostano** P, Reymond A, Dummer R, Raffoul W, Hoetzenecker W, Hofbauer GFL Dotto GP Loss of mesenchymal CSL signaling leads to a field cancerization phenotype with multifocal epithelial tumor development *Cell* 149:1207-1220 (2012)
86. Ubaldi S, Calura E, Beltrame L, Fuso Nerini I, Marchini S, Cavalieri D, Erba E, **Chiorino** G, **Ostano** P, D'Angelo D, D'Incalci1 M, Romualdi C A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma *PLoS One*7:e35423 (2012)
87. Albino D, Longoni N, Curti L, **Mello Grand** M, Pinton S, Malek A, Civenni G, Thalmann G, D'Ambrosio G, Sarti M, Sessa F, **Chiorino** G, Catapano CV Carbone GM ESE3/EHF Controls Epithelial Cell Differentiation and Its Loss Leads to Prostate Tumors with Mesenchymal, Stem-like and Basal Cell Features *Cancer Res* 72:2889-2900 (2012)
88. **Ostano** P, Bione S, Belgiovine C, Chiodi I, **Ghimenti** C, Scovassi AI, **Chiorino** G, Mondello C Cross-Analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation *OMICS* 16: 24-36 (2012)
89. Della Vittoria Scarpati G, Falchetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, **Singh** VK, D'Incalci M, De Placido S, Pepe S A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer *Int J Radiat Oncol Biol Phys* 83:1113-1119 (2012)

90. Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, **Chiorino** G, Digiandomenico S, Rocchi M, Capozzi O, Margison G, Watson A, Caccuri A, Pastore A, Fossati A, Mantovani R, **Grosso** F, Tercero J, Erba E, D'Incalci M. Characterization of a new trabectedin resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents *Int J Cancer* 131: 59-69 (2012)
91. Chikh A, Matin R, Senatore V, Hufbauer M, Lavery D, Raimondi C, **Ostano** P, **Mello-Grand** M, **Ghimenti** C, Bahta A, Khalaf S, Akgul B, Braun K, **Chiorino** C, Philpott M, Harwood C, Bergamaschi D. IASPP/p63 auto-regulatory feedback loop is required for the homeostasis of stratified epithelia *EMBO J* 30: 4261-4273 (2011)
92. Fregnan F, Petrov V, Garzotto D, De Marchis S, Offenhäuser N, **Grosso** E, **Chiorino** G, Perroteau I. Eps8 involvement in neuregulin1-ErbB4 mediated migration in the neuronal progenitor cell line ST14A. *Exp Cell Res*. 317: 757-769 (2011)
93. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, **Chiorino** G, Buda A, Romualdi C, D'Incalci M. Association between miR-200c and survival of stage I epithelial ovarian cancer patients. A retrospective study on two independent tumour tissue collections. *Lancet Oncol*. 12: 273-285 (2011)
94. **Peraldo-Neia** C, Migliardi G, **Mello-Grand** M, Montemurro F, **Segir** R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, **Chiorino** G, Aglietta M. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. *BMC Cancer* 11: 31 (2011)
95. Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, **Peraldo-Neia** C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. *Breast Cancer Res Treat* 130:29-40. (2011)
96. Pignochino Y, Sarotto I, **Peraldo-Neia** C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, **Chiorino** G, Risio M, Bardelli A, Aglietta M, Leone F. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. *BMC Cancer* 10: 631 (2010)
97. Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, **Favero** F, **Mello-Grand** M, Dei Tos AP, Giulotto E, Tarabozetti G, D'Incalci M, Mondello C. Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells. *PLoS One* 5: e14154 (2010)
98. **Ghimenti** C, **Mello Grand** M, Regolo L, Zambelli A, **Chiorino** G. Absence of K303R Estrogen Receptor- Mutation in Breast Cancer Patients with Different Response to Aromatase Inhibitor Anastrozole Neoadjuvant Treatment. *Exp Ther Med* 1: 939-942 (2010)
99. **Mello-Grand** M, **Singh** V, **Ghimenti** C, **Scatolini** M, Regolo L, **Grosso** E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, **Chiorino** G. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. *Breast Cancer Res Treat* 21: 399-411 (2010)
100. Kunderfranco P, **Mello-Grand** M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, **Chiorino** G, Catapano CV, Carbone GM. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. *PLoS One* 5: e10547 (2010)
101. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D'Arena G, **Chiorino** G, Malavasi F. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. *Mol Med* 16: 87-91 (2010)



102. **Scatolini M, Mello Grand M, Grosso E, Venesio T, Pisacane A, Balsamo A, Sirovich R, Risio M, Chiorino G.** Altered molecular pathways identify different histotypes within melanoma progression. *Int J Cancer* 126: 1869-1881 (2010)
103. **Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G.** MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. *Am J Respir Cell Mol Biol* 42: 312-319 (2010).
104. **Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP.** A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. *J Clin Invest.* 119: 3127-3137 (2009)
105. **Azzimonti B, Dell'Oste V, Borgogna C, Mondini M, Gugliesi F, De Andrea M, Chiorino G, Scatolini M, Ghimenti C, Landolfo S, Gariglio M.** Epithelial-mesenchymal transition induced by keratinocytes growth condition is overcome by E6 and E7 from HPV16 but not HPV8 and HPV38: characterization of their global transcription profile. *Virology* 388: 260-269 (2009)
106. **Bekkal-Brikci F, Chiorino G, Boushaba K.** G1/S transition and cell population dynamics. *Networks and Heterogeneous Media*, 4: 67-90 (2009)
107. **Duó D, Ghimenti C, Migliora P, Pavanelli MC, Mastracci L, Angeli G.** Identification and characterization of human papillomavirus (HPV) DNA sequences in Italian breast cancer patients by PCR and LIPA (line probe assay) reverse hybridisation. *Molecular Medicine Reports* 1: 673-677 (2008)
108. **Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L, Garbi A, Torri V, Dell'Anna T, Apolone G, Broggin M, D'Incalci M.** Analysis of gene expression in early-stage ovarian cancer. *Clin Cancer Res* 14: 7850-7860 (2008)
109. **Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, Camussi G, Matera L.** Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. *Vaccine* 26: 6422-6432 (2008)
110. **Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani MR.** Identification of new tumor endothelial markers through gene expression profiling. *BMC Genomics* 9: 201 (2008)
111. **Venesio T, Chiorino G, Balsamo A, Zaccagna A, Petti C, Pisacane A, Sarotto I, Scatolini M, Picciotto F, Risio M.** In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. *Mod Pathol* 21: 716-726 (2008)
112. **Mandinova A, Lefort K, Tommasi di Vignano A, Stonely W, Ostano P, Chiorino G, Iwaki H, Nakanishi J, Dotto GP.** FoxO3a is a key transcriptional target of canonical Notch signaling in the keratinocyte UVB-response. *EMBO J* 27: 1243-1254 (2008)
113. **Chiorino G, Mello Grand M, Scatolini M, Ostano P.** From single gene to integrative molecular concept maps: pitfalls and potentials of the technology of microarrays. *J Biol Regul Homeost Agents* 22: 7-16 (2008)
114. **Cangemi R, Mensa A, Alberini V, Mello Grand M, Chiorino G, Catapano CV, Carbone G.** Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. *Oncogene* 27: 2877-2885 (2007)
115. **Salvati E, Legnetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, Sperduti I, Stevens M, D'Incalci M, Blasco M, Chiorino G, Horard B, Gilson E, Zupi G, Biroccio A.** Telomere Damage promotes antitumoral activity of the G-quadruplex ligand RHPS4. *J Clin Invest* 117: 3236-3247 (2007)
116. **Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, Omede' P, Scatolini M, Jaksic O, Chiorino G, Efremov D, Malavasi F.** CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. *Blood* 110:4012-4021 (2007)
117. **Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, Devgan V, Lieb J, Raffoul W, Hohl D, Neel V, Garlick J, Chiorino G, Dotto GP.** Notch1 is a p53 target gene involved in human

- keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. *Genes Dev* 21: 562-577 (2007)
118. Nguyen BC, Wang J, Devgan V, Lefort K, Buck C, Antonini D, Kitajewski J, **Chiorino** G, Missero C, Dotto GP. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. *Genes Dev* 20: 1028-1042 (2006)
119. Benassi B, Fanciulli M, Fiorentino F, Porrello A, **Chiorino** G, Loda M, Zupi G, Biroccio A. Myc phosphorylation is required for cellular response to oxidative stress. *Mol Cell* 21: 509-519 (2006)
120. Grossi M, Hiou-Feige A, Di Vignano AT, Calautti E, **Ostano** P, Lee S, **Chiorino** G, Dotto GP. Negative control of keratinocyte differentiation by Rho/CRIK signaling coupled with up-regulation of KyoT1/2 (FHL1) expression. *Proc Natl Acad Sci USA* 102: 11313-11318 (2005)
121. Marchini S, Marrazzo E, Bonomi R, **Chiorino** G, Zaffaroni M, Weissbach L, Hornicek FJ, Broggin M, Faircloth GT, D'Incalci M. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. *Eur J Cancer* 41: 323-333 (2005)
122. **Chiorino** G, **Acquadro** F, **Viscomi** S, **Mello Grand** M, **Segir** R, Dotto GP. Interpretation of expression profiling results obtained from different platforms and tissue sources: an example from prostate cancer data. *Eur J Cancer* 40: 2592-2603 (2004)
123. Okuyama R, Nguyen BC, Talora C, Lioumi M, **Chiorino** G, Tagami H, Woo M, Dotto GP. High commitment of embryonic keratinocytes to terminal differentiation through a Notch1 - caspase 3 regulatory loop. *Dev Cell* 6: 551-562 (2004)
124. Marchini S, **Chiorino** G, Faircloth GT, D'Incalci M. Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines. *J Biol Regul Homeost Agents* 16: 241-248 (2002)
125. Erba E, Bassano L, Di Liberti G, Muradore I, **Chiorino** G, Ubezio P, Vignati S, Codegoni A, Desiderio MA, Faircloth G, Jimeno J, D'Incalci M. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. *Br J Cancer* 86: 1510-1517 (2002)
126. **Chiorino** G, Lupi M. Variability in the timing of G1/S transition. *Math Biosci* 177-178: 85-101 (2002)
127. Marchini S S, **Chiorino** G. Use of the microarrays to study the mechanism of action of new anticancer drugs. *Minerva Biotechnologica* 13:269-280 (2001)